Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 13, 2007, detailing two significant events that occurred in early August. First, the company announced on August 8th that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for rilonacept, a treatment for Cryopyrin-Associated Periodic Syndromes (CAPS), and has granted it priority review status. This signifies a critical step towards potential market approval for this novel IL-1 Trap therapy. Furthermore, on August 13th, Regeneron reported receiving a $20 million milestone payment from Bayer HealthCare. This payment was triggered by the dosing of the first patient in a Phase 3 study for VEGF Trap-Eye, a treatment candidate for neovascular age-related macular degeneration (wet AMD). These developments highlight progress in both late-stage clinical development and regulatory review for key pipeline assets.
Key Highlights
- 1FDA accepted BLA for rilonacept (IL-1 Trap) for CAPS and granted Priority Review.
- 2Rilonacept is being investigated for long-term treatment of Cryopyrin-Associated Periodic Syndromes (CAPS).
- 3Received a $20 million milestone payment from Bayer HealthCare.
- 4Milestone payment was triggered by the first patient dosed in the Phase 3 study of VEGF Trap-Eye.
- 5VEGF Trap-Eye is being studied for the neovascular form of age-related macular degeneration (wet AMD).